Narrow By

Press releases

1 2 3 30

BD Announces Publication of an Independent Analysis of Drug-Coated Balloon Safety Data for Femoropopliteal Peripheral Arterial Disease

Sep 28, 2019

BD announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug Coated Balloon (DCB) femoropopliteal clinical program in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

BD Announces Leadership Succession Plan

Sep 26, 2019

BD Announces Leadership Succession Plan Thomas E. Polen Appointed Chief Executive Officer, Effective Jan. 28, 2020 Vincent A. Forlenza to Continue as Executive Chairman of the Board

Community Clinics Receive Grant for Point-of-Care Diagnostics

Sep 19, 2019

As part of a continued effort to support and improve evidence-based care in community clinics, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, in conjunction with Heart to Heart International (HHI) and the National Association of Free and Charitable Clinics (NAFC) today announced product-based grants to six clinics across the U.S. through the Point of Care, Enhancing Clinical Effectiveness (PoCECE) program.

BD awards $1.2 million in grants to community health centers that help vulnerable patients more effectively manage medications

Aug 29, 2019

BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (NACHC) recently honored six community health centers in the U.S. with the “Innovations in Care” award in recognition of their success in low-resource areas identifying and assisting vulnerable people to better manage complex chronic diseases and improve their health.

BD Statement on FDA Recommendations to Health Care Providers Regarding Paclitaxel-Coated Devices

Aug 9, 2019

BD stands behind the safety of its LUTONIX® DCB and is committed to improving the quality of life for patients with PAD. To ensure patients receive the best care possible, BD’s broad range of treatment options for this serious disease will continue to be available for health care providers.

BD Announces Results for 2019 Third Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

Aug 6, 2019

BD Announces Results for 2019 Third Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

BD Statement on Georgia Facilities

Jul 25, 2019

BD Statement on Georgia Facilities

BD releases 2018 Sustainability Report

Jul 23, 2019

BD today issued its 2018 Sustainability Report, focusing on management of the environmental, social and governance factors that support the company’s 2020 Sustainability Goals.

United States and Indonesia Expand Collaboration to End Tuberculosis

Jun 27, 2019

Today, the United States Government through the United States Agency for International Development (USAID) and BD (Becton, Dickinson and Company), a U.S.-based global medical technology company, formalized a new partnership to support Indonesia in eliminating tuberculosis (TB) through its National Tuberculosis Program.

BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices

Jun 20, 2019

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting related to the potential increase in mortality associated with the use of paclitaxel-coated devices in patients with peripheral arterial disease (PAD) in the superficial femoropopliteal artery (SFA):

1 2 3 30

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.